180 related articles for article (PubMed ID: 28874004)
1. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
Zhang Z; Chan AK; Ding X; Li Y; Zhang R; Chen L; Liu Y; Wang Y; Xiong J; Ng HK; Yao Y; Zhou L
Neuro Oncol; 2017 Jul; 19(7):1008-1010. PubMed ID: 28874004
[No Abstract] [Full Text] [Related]
2. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
[No Abstract] [Full Text] [Related]
5. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
[TBL] [Abstract][Full Text] [Related]
6. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Eckel-Passow JE; Lachance DH; Molinaro AM; Walsh KM; Decker PA; Sicotte H; Pekmezci M; Rice T; Kosel ML; Smirnov IV; Sarkar G; Caron AA; Kollmeyer TM; Praska CE; Chada AR; Halder C; Hansen HM; McCoy LS; Bracci PM; Marshall R; Zheng S; Reis GF; Pico AR; O'Neill BP; Buckner JC; Giannini C; Huse JT; Perry A; Tihan T; Berger MS; Chang SM; Prados MD; Wiemels J; Wiencke JK; Wrensch MR; Jenkins RB
N Engl J Med; 2015 Jun; 372(26):2499-508. PubMed ID: 26061753
[TBL] [Abstract][Full Text] [Related]
7. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
9. Molecular categorisation of gliomas.
Burki TK
Lancet Oncol; 2015 Jul; 16(7):e320. PubMed ID: 26095778
[No Abstract] [Full Text] [Related]
10. The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas.
Xu J; Xu FP; Liu ZH; Cui Q; Zhang KP; Li Z
Medicine (Baltimore); 2022 Jul; 101(29):e29668. PubMed ID: 35866817
[TBL] [Abstract][Full Text] [Related]
11. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
[TBL] [Abstract][Full Text] [Related]
12. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
[TBL] [Abstract][Full Text] [Related]
13. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
Labreche K; Kinnersley B; Berzero G; Di Stefano AL; Rahimian A; Detrait I; Marie Y; Grenier-Boley B; Hoang-Xuan K; Delattre JY; Idbaih A; Houlston RS; Sanson M
Acta Neuropathol; 2018 May; 135(5):743-755. PubMed ID: 29460007
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
[TBL] [Abstract][Full Text] [Related]
15. Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.
Lee J; Putnam AR; Chesier SH; Banerjee A; Raffel C; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Perry A; Solomon DA
Acta Neuropathol Commun; 2018 Sep; 6(1):95. PubMed ID: 30231927
[No Abstract] [Full Text] [Related]
16. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
18. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
Komori T
Lab Invest; 2022 Feb; 102(2):126-133. PubMed ID: 34504304
[TBL] [Abstract][Full Text] [Related]
19. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]